Introduction {#sec1}
============

Cancer is a major public health problem worldwide. According to GLOBOCAN worldwide estimates, an estimated 14.1 million new cancer cases and 8.2 million cancer-related deaths occurred in 2012 \[[@B1]\]. In addition, the incidence of cancer is predicted to reach 25 million worldwide by 2032 \[[@B2]\]. This growing cancer burden is expected as populations expand and age. Meanwhile, certain lifestyles, such as alcohol consumption, are likely to further boost the burden \[[@B1]\].

Alcohol consumption is the third-largest risk factor for global health burden \[[@B4]\]. Approximately 3.3 million deaths, almost 5.9% of total deaths worldwide in 2012, were attributable to alcohol consumption \[[@B5]\]. As early as 2002, approximately 3.6% of all cancers and 3.5% of all cancer deaths were reported due to alcohol consumption \[[@B3]\]. It is well established that alcohol is first catalytically oxidized to acetaldehyde, mainly by alcohol dehydrogenases (ADH), and then to harmless acetate by aldehyde dehydrogenases (ALDH) \[[@B6],[@B7]\]. Acetaldehyde may stimulate carcinogenesis by disrupting DNA synthesis and repair, inhibiting DNA methylation, and by interacting with retinoid metabolism \[[@B8],[@B9]\]. Genetic polymorphisms of alcohol-metabolism genes result in differences between individuals in exposure to acetaldehyde, leading to possible carcinogenic effects \[[@B10]\]. Amongst them, Arg47His (rs1229984 G \> A) in *ADH1B* have been frequently studied for its potential effect on the carcinogenesis. Compared with the Arg/Arg individuals, the His/His individuals have a 40-fold higher enzyme activity oxidized alcohol to toxic acetaldehyde \[[@B7]\].

Epidemiologic studies have extensively explored the association between *ADH1B* Arg47His polymorphism and cancer risk. However, the findings are as yet inconclusive. Several meta-analyses published before 2016 associated this polymorphism only with esophageal, head and neck, gastric, colorectal, and upper aerodigestive tract cancer \[[@B11]\]. However, no meta-analyses have ever investigated the association between *ADH1B* Arg47His polymorphism and overall cancer risk, including other types of cancer. In addition, several more studies with larger sample size were published since 2016 \[[@B17]\]. Therefore, we performed an updated meta-analysis including the most recent and relevant studies to clarify the association between *ADH1B* Arg47His polymorphism and the overall cancer risk, involving 66 studies with 31999 cases and 50964 controls \[[@B17]\].

Methods {#sec2}
=======

Identification of relevant studies {#sec2-1}
----------------------------------

A systematic literature search was conducted in the following electronic databases: Medline and Embase database up to 1 July 2018. The following search terms were used: 'ADH1B or ADH2' or 'polymorphism or variant' or 'cancer or carcinoma or tumor'. In addition, reviews and references lists of eligible studies were manually searched to identify additional relevant articles.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

The eligible articles must meet the following criteria. The inclusion criteria were as follows: (i) studies evaluating the association between *ADH1B* Arg47His polymorphism and overall cancer risk; (ii) case--control studies; (iii) studies with sufficient information to calculate the odds ratio (OR) and its 95% confidence interval (CI). The major exclusion criteria were as follows: (i) no control group; (ii) duplicate publication; (iii) reviews, meta-analyses, conference reports, or editorial articles; (iv) no available data.

Data extraction {#sec2-3}
---------------

Investigators independently extracted the relevant information from all eligible studies according to the inclusion and exclusion criteria listed above. A final consensus was achieved regarding each selected study. The following information was extracted from each study: first author's surname, publication year, country, ethnicity, cancer type, control source, genotyping method, number of cases and controls with different genotypes, and Hardy--Weinberg equilibrium (HWE) of genotypes in controls.

Statistical analysis {#sec2-4}
--------------------

The strength of the association between *ADH1B* Arg47His polymorphism and overall cancer risk was evaluated by calculating ORs and 95% CIs. The pooled ORs were also estimated using homozygous model (His/His vs. Arg/Arg), heterozygous model (Arg/His vs. Arg/Arg), recessive model \[His/His vs. (Arg/His + Arg/Arg)\], dominant model \[(Arg/His + His/His) vs. Arg/Arg\], as well as allele comparison (His vs. Arg). Stratification analyses were further conducted according to ethnicity, cancer type, control source, and HWE. Chi square-based Q-test was applied to assess between-study heterogeneity. If no heterogeneity (*P*\>0.10) was found, the fixed-effect model (Mantel--Haenszel method) was performed \[[@B81]\]. Otherwise, the random-effect model (DerSimonian and Laird method) was used \[[@B82]\]. Sensitivity analysis was carried out to assess the stability of the results, and potential publication bias was assessed with Begg's funnel plot and Egger's linear regression test \[[@B83]\]. All the statistical analyses were calculated using STATA software (version 11.0, Stata Corporation, College Station, TX). A *P*-value less than 0.05 was considered statistically significant.

Results {#sec3}
=======

Study characteristics {#sec3-1}
---------------------

As listed in [Figure 1](#F1){ref-type="fig"}, a total of 432 potential records were initially identified from Medline and Embase using the search terms listed above. After a screening of the titles and abstracts, 146 publications were subjected for further evaluation. Of them, 59 articles were excluded for irrelevant information, 13 for only meta-analysis, 12 for no sufficient data, and 1 was excluded for duplicate study. In addition, three studies were manually identified from reviews and references lists of the eligible studies. Ultimately, 64 articles investigating the association between *ADH1B* Arg47His polymorphism and cancer risk were included in the final meta-analysis \[[@B17]\].

![Flow chart of studies included in our meta-analysis](bsr-39-bsr20181915-g1){#F1}

Overall, 66 studies from 64 articles with 31999 cases and 50964 controls were finally included in our meta-analysis. As shown in [Table 1](#T1){ref-type="table"}, there were 48 studies conducted amongst Asians, 15 amongst Caucasians, and 3 amongst mixed ethnic group. With respect to cancer type, 23 studies addressed esophageal cancer, 16 head and neck cancer, 10 colorectal cancer, 6 gastric cancer, 4 hepatocellular, 3 upper aerodigestive tract cancer, 2 pancreatic and 1 bladder and breast cancer. Regarding control source, 34 studies were hospital-based and 32 studies were population-based. With respect to HWE, 52 met HWE, 5 departed from HWE, and 9 had not enough information.

###### Main characteristics of included studies in our meta-analysis

  Author                   Year   Country    Ethnicity   Cancer type      Control source   Genotyping method   Number of cases   Number of controls                       HWE                                                                                                                                
  ------------------------ ------ ---------- ----------- ---------------- ---------------- ------------------- ----------------- ---------------------------------------- ---------------------------------------- ------ ---------------------------------------- ----------------------------------------- -----
  Zhong                    2016   China      Asian       Colorectal       HB               PCR-RFLP            85                125                                      64                                       152    172                                      34                                        Yes
  Masaoka                  2016   Japan      Asian       Bladder          HB               TaqMan              3                 38                                       33                                       27     265                                      448                                       Yes
  Liu                      2016   China      Asian       Hepatocellular   HB               Affymetrix          48                262                                      283                                      236    1229                                     1748                                      Yes
  Kagemoto                 2016   Japan      Asian       Esophageal       PB               Multiplex PCR       31                36                                       50                                       60     389                                      676                                       Yes
  Chen                     2016   China      Asian       Gastric          HB               PCR-RFLP            83                117                                      46                                       104    125                                      45                                        Yes
  Ji                       2015   Korea      Asian       Head and neck    HB               TaqMan              26                107                                      127                                      15     125                                      190                                       Yes
  Hidaka                   2015   Japan      Asian       Gastric          PB               TaqMan              32                173                                      252                                      35     168                                      254                                       Yes
  Bediaga                  2015   Spain      Caucasian   Head and neck    PB               TaqMan              78                6[^1^](#T1TFN1){ref-type="table-fn"}     6[^1^](#T1TFN1){ref-type="table-fn"}     203    39[^1^](#T1TFN1){ref-type="table-fn"}    39 [^1^](#T1TFN1){ref-type="table-fn"}    NA
  Ye                       2014   China      Asian       Esophageal       HB               PCR-RFLP            224               400                                      377                                      150    578                                      663                                       Yes
  Tsai                     2014   China      Asian       Head and neck    HB               TaqMan              47                165                                      224                                      25     221                                      268                                       No
  Chung                    2014   China      Asian       UADT             HB               MassARRAY           68                76                                       108                                      25     111                                      125                                       Yes
  Yuan                     2013   China      Asian       Head and neck    PB               TaqMan              42                180                                      170                                      72     362                                      455                                       Yes
  Wu                       2013   China      Asian       Esophageal       PB               TaqMan              138               309                                      355                                      101    410                                      510                                       Yes
  Gao                      2013   China      Asian       Esophageal       PB               TaqMan              252               907                                      939                                      199    909                                      1155                                      Yes
  Dura                     2013   Dutch      Caucasian   Esophageal       PB               TaqMan              326               20                                       0                                        406    23                                       0                                         Yes
  Crous-Bou                2013   Spain      Caucasian   Colorectal       PB               Illumina            457               324                                      79                                       513    360                                      54                                        Yes
  Liang                    2012   Island     Mixed       Head and neck    PB               TaqMan              530               38                                       5                                        593    76                                       15                                        No
  Gu                       2012   China      Asian       Esophageal       HB               MassArray           53                168                                      158                                      26     170                                      182                                       Yes
  Ferrari                  2012   France     Caucasian   Colorectal       PB               TaqMan              1129              97                                       5                                        1800   176                                      6                                         Yes
  Duell                    2012   Spain      Caucasian   Gastric          PB               Illumina            317               45                                       2                                        1133   132                                      6                                         Yes
  Chiang                   2012   China      Asian       Colorectal       HB               PCR-RFLP            7                 34                                       62                                       43     205                                      297                                       Yes
  Yin                      2011   Japan      Asian       Colorectal       PB               PCR-RFLP            25                161                                      268                                      71     393                                      588                                       Yes
  Wang                     2011   China      Asian       Esophageal       HB               PCR-CTPP            15                34                                       33                                       17     67                                       78                                        Yes
  McKay                    2011   France     Caucasian   UADT             PB               Illumina            6776              416[^1^](#T1TFN1){ref-type="table-fn"}   416[^1^](#T1TFN1){ref-type="table-fn"}   7742   907[^1^](#T1TFN1){ref-type="table-fn"}   907 [^1^](#T1TFN1){ref-type="table-fn"}   NA
  Marichalar-Mendia        2011   Spain      Caucasian   Head and neck    PB               TaqMan              80                7[^1^](#T1TFN1){ref-type="table-fn"}     7[^1^](#T1TFN1){ref-type="table-fn"}     203    39[^1^](#T1TFN1){ref-type="table-fn"}    39 [^1^](#T1TFN1){ref-type="table-fn"}    NA
  Ji                       2011   Korea      Asian       Head and neck    HB               TaqMan              30                87                                       108                                      15     112                                      174                                       Yes
  Hakenewerth              2011   U.S.A.     Mixed       Head and neck    PB               Illumina            1192              31[^1^](#T1TFN1){ref-type="table-fn"}    31[^1^](#T1TFN1){ref-type="table-fn"}    1243   79[^1^](#T1TFN1){ref-type="table-fn"}    79[^1^](#T1TFN1){ref-type="table-fn"}     NA
  Wei                      2010   U.S.A.     Caucasian   Head and neck    HB               PCR-RFLP            1059              51                                       0                                        1075   52                                       2                                         Yes
  Tanaka                   2010   Japan      Asian       Esophageal       HB               Affymetrix          151               591[^1^](#T1TFN1){ref-type="table-fn"}   591[^1^](#T1TFN1){ref-type="table-fn"}   44     776[^1^](#T1TFN1){ref-type="table-fn"}   776 [^1^](#T1TFN1){ref-type="table-fn"}   NA
  Soucek                   2010   Czech      Caucasian   Head and neck    HB               TaqMan              101               21                                       0                                        111    10                                       1                                         Yes
  Mohelnikova- Duchonova   2010   Czech      Caucasian   Pancreatic       PB               TaqMan              213               22                                       0                                        242    22                                       1                                         Yes
  Garcia                   2010   Brazil     Mixed       Head and neck    HB               PCR-RFLP            195               12                                       0                                        213    29                                       2                                         Yes
  Cao                      2010   China      Asian       Gastric          PB               DHPLC               40                148                                      194                                      29     160                                      193                                       Yes
  Yang                     2009   China      Asian       Colorectal       HB               SNPLex              39                181                                      205                                      62     319                                      370                                       Yes
  Oze                      2009   Japan      Asian       UADT             HB               TaqMan              71                222                                      292                                      53     408                                      709                                       Yes
  Kawase                   2009   Japan      Asian       Breast           HB               TaqMan              25                162                                      265                                      47     322                                      539                                       Yes
  Kanda                    2009   Japan      Asian       Pancreatic       HB               TaqMan              4                 55                                       101                                      74     551                                      975                                       Yes
  Ding                     2009   China      Asian       Esophageal       PB               DHPLC               8                 75                                       108                                      19     96                                       106                                       Yes
  Cui                      2009   Japan      Asian       Esophageal       PB               Illumina            194               363                                      510                                      151    986                                      1626                                      Yes
  Akbari                   2009   Iran       Asian       Esophageal       PB               MassARRAY           21                232                                      490                                      73     471                                      827                                       Yes
  Solomon                  2008   India      Asian       Head and neck    HB               PCR-RFLP            13                56                                       57                                       8      38                                       54                                        Yes
  Lee                      2008   China      Asian       Esophageal       HB               PCR-RFLP            117               149                                      140                                      46     275                                      335                                       Yes
  Guo                      2008   China      Asian       Esophageal       HB               PCR-RFLP            17                25                                       38                                       24     168                                      288                                       Yes
  Gao                      2008   China      Asian       Colorectal       PB               DHPLC               15                73                                       102                                      20     109                                      93                                        Yes
  Ding                     2008   China      Asian       Hepatocellular   PB               PCR-RFLP            21                132                                      54                                       26     97                                       84                                        Yes
  Zhang                    2007   U.S.A.     Caucasian   Gastric          PB               TaqMan              261               31                                       1                                        352    48                                       1                                         Yes
  Yin                      2007   Japan      Asian       Colorectal       PB               PCR-RFLP            40                294                                      345                                      37     289                                      452                                       Yes
  Yang                     2007   China      Asian       Esophageal       PB               PCR-CTPP            33                80                                       78                                       22     76                                       100                                       Yes
  Hiraki                   2007   Japan      Asian       Head and neck    HB               TaqMan              26                75                                       138                                      31     213                                      471                                       Yes
  Asakage                  2007   Japan      Asian       Head and neck    PB               PCR-RFLP            31                223                                      388                                      19     28                                       49                                        No
  Sakamoto                 2006   Japan      Asian       Hepatocellular   HB               PCR-CTPP            12                73                                       124                                      13     103                                      159                                       Yes
  Matsuo                   2006   Japan      Asian       Colorectal       HB               PCR-CTPP            19                102                                      136                                      36     259                                      473                                       Yes
  Hashibe                  2006   France     Caucasian   Head and neck    HB               TaqMan              719               47[^1^](#T1TFN1){ref-type="table-fn"}    47[^1^](#T1TFN1){ref-type="table-fn"}    877    108[^1^](#T1TFN1){ref-type="table-fn"}   108 [^1^](#T1TFN1){ref-type="table-fn"}   NA
  Hashibe                  2006   France     Caucasian   Esophageal       HB               TaqMan              163               4[^1^](#T1TFN1){ref-type="table-fn"}     4[^1^](#T1TFN1){ref-type="table-fn"}     792    95[^1^](#T1TFN1){ref-type="table-fn"}    95 [^1^](#T1TFN1){ref-type="table-fn"}    NA
  Chen                     2006   China      Asian       Esophageal       HB               PCR-RFLP            88                117                                      125                                      39     240                                      313                                       Yes
  Yang                     2005   China      Asian       Esophageal       HB               PCR-CTPP            6                 85                                       74                                       22     168                                      304                                       Yes
  Wu                       2005   China      Asian       Esophageal       PB               PCR-RFLP            39                49                                       46                                       16     191                                      130                                       No
  Landi                    2005   France     Caucasian   Colorectal       HB               Millipore           292               54                                       2                                        263    48                                       3                                         Yes
  Risch                    2003   Germany    Caucasian   Head and neck    PB               PCR-RFLP            227               18                                       0                                        227    24                                       0                                         Yes
  Chao                     2003   China      Asian       Esophageal       HB               PCR-RFLP            19                41                                       28                                       7      43                                       55                                        Yes
  Yokoyama                 2002   Japan      Asian       Esophageal       PB               PCR-RFLP            51                73                                       110                                      31     220                                      383                                       Yes
  Boonyaphiphat            2002   Thailand   Asian       Esophageal       HB               APLP                15                86                                       101                                      28     139                                      94                                        No
  Yokoyama                 2001   Japan      Asian       Esophageal       PB               PCR-RFLP            56                56[^1^](#T1TFN1){ref-type="table-fn"}    56[^1^](#T1TFN1){ref-type="table-fn"}    145    381[^1^](#T1TFN1){ref-type="table-fn"}   381 [^1^](#T1TFN1){ref-type="table-fn"}   NA
  Yokoyama                 2001   Japan      Asian       Gastric          PB               PCR-RFLP            28                10[^1^](#T1TFN1){ref-type="table-fn"}    10[^1^](#T1TFN1){ref-type="table-fn"}    145    381[^1^](#T1TFN1){ref-type="table-fn"}   381 [^1^](#T1TFN1){ref-type="table-fn"}   NA
  Takeshita                2000   Japan      Asian       Hepatocellular   PB               PCR-RFLP            3                 36                                       63                                       8      43                                       74                                        Yes
  Hori                     1997   Japan      Asian       Esophageal       HB               PCR-RFLP            20                31                                       40                                       5      20                                       43                                        Yes

Abbreviations: APLP, amplified product length polymorphism; DHPLC, denaturing high-performance liquid chromatography; HB, hospital-based, NA, not applicable; PB, population-based; PCR-CTPP, PCR with the confronting-two-pair primer; PCR-RFLP, PCR-restriction fragment length polymorphism; UADT, upper aerodigestive tract.

The number of GA + AA.

Meta-analysis results {#sec3-2}
---------------------

The main results for the association between *ADH1B* Arg47His polymorphism and cancer risk are shown in [Table 2](#T2){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}. We found that *ADH1B* Arg47His polymorphism significantly associated with the decreased risk of overall cancer under all the five genetic models: homozygous model, OR = 0.62, 95% CI = 0.49--0.77; heterozygous model, OR = 0.71, 95% CI = 0.60--0.84; recessive model, OR = 0.83, 95% CI = 0.76--0.91; dominant model, OR = 0.62, 95% CI = 0.53--0.72; and allele comparison, OR = 0.82, 95% CI = 0.75--0.89.

![Forest plot of the association between *ADH1B* Arg47His polymorphism and the overall cancer risk under the allele comparison model](bsr-39-bsr20181915-g2){#F2}

###### Meta-analysis of the association between the ADH1B Arg47His and cancer risk

  Variables          Sample size Case/control   Homozygous              Heterozygous   Recessive               Dominant   Allele comparison                                                                           
  ------------------ -------------------------- ----------------------- -------------- ----------------------- ---------- ----------------------- --------- ----------------------- --------- ----------------------- ---------
  Total              31999/50964                **0.62 (0.49--0.77)**   \<0.001        **0.71 (0.60--0.84)**   \<0.001    **0.83 (0.76--0.91)**   \<0.001   **0.62 (0.53--0.72)**   \<0.001   **0.82 (0.75--0.89)**   \<0.001
  Ethnicity                                                                                                                                                                                                           
    Asian            17057/31885                **0.60 (0.48--0.76)**   \<0.001        **0.66 (0.53--0.81)**   \<0.001    **0.82 (0.75--0.91)**   \<0.001   **0.58 (0.47--0.72)**   \<0.001   **0.80 (0.72--0.88)**   \<0.001
    Caucasian        12970/16908                **1.45 (1.05--2.02)**   0.727          1.01 (0.90--1.13)       0.570      **1.45 (1.05--2.00)**   0.712     0.81 (0.64--1.03)       \<0.001   1.06 (0.96--1.17)       0.569
    Mixed            1972/2171                  **0.35 (0.13--0.93)**   0.743          **0.53 (0.37--0.75)**   0.606      **0.37 (0.14--0.98)**   0.751     **0.46 (0.36--0.60)**   0.651     **0.50 (0.36--0.68)**   0.545
  Cancer type                                                                                                                                                                                                         
    Colorectal       4821/7697                  1.19 (0.82--1.72)       \<0.001        0.99 (0.88--1.11)       0.857      1.19 (0.91--1.55)       \<0.001   1.03 (0.88--1.21)       0.099     1.05 (0.90--1.23)       \<0.001
    Hepatocellular   1111/3820                  0.84 (0.64--1.10)       0.541          1.16 (0.84--1.61)       0.328      0.81 (0.61--1.08)       0.041     0.98 (0.76--1.28)       0.452     0.88 (0.76--1.02)       0.270
    Esophageal       9117/15930                 **0.39 (0.28--0.55)**   \<0.001        **0.47 (0.34--0.64)**   \<0.001    **0.72 (0.62--0.83)**   \<0.001   **0.41 (0.31--0.54)**   \<0.001   **0.67 (0.57--0.78)**   \<0.001
    Gastric          1770/2930                  1.02 (0.76--1.36)       0.637          1.03 (0.84--1.27)       0.356      1.02 (0.86--1.22)       0.973     0.77 (0.48--1.23)       \<0.001   1.03 (0.92--1.16)       0.629
    Head and neck    6646/7901                  **0.55 (0.31--0.97)**   \<0.001        0.77 (0.52--1.12)       \<0.001    **0.78 (0.66--0.93)**   0.092     **0.64 (0.47--0.87)**   \<0.001   **0.80 (0.66--0.96)**   \<0.001
    UADT             7613/9173                  **0.31 (0.23--0.42)**   0.921          **0.33 (0.21--0.53)**   0.161      **0.70 (0.57--0.86)**   0.260     **0.39 (0.26--0.58)**   0.010     **0.62 (0.54--0.71)**   0.924
    Pancreatic       395/1865                   1.65 (0.62--4.38)       0.345          1.29 (0.76--2.20)       0.430      1.09 (0.78--1.52)       0.513     1.26 (0.75--2.13)       0.358     1.12 (0.86--1.45)       0.774
  Control source                                                                                                                                                                                                      
    HB               10560/20932                **0.53 (0.40--0.71)**   \<0.001        **0.64 (0.51--0.81)**   \<0.001    **0.79 (0.69--0.90)**   \<0.001   **0.56 (0.44--0.72)**   \<0.001   **0.77 (0.68--0.87)**   \<0.001
    PB               21439/30032                0.75 (0.52--1.07)       \<0.001        0.79 (0.61--1.02)       \<0.001    0.89 (0.78--1.02)       \<0.001   **0.68 (0.54--0.85)**   \<0.001   **0.87 (0.76--0.99)**   \<0.001
  HWE                                                                                                                                                                                                                 
    YES              20769/37678                **0.60 (0.48--0.76)**   \<0.001        **0.71 (0.60--0.84)**   \<0.001    **0.81 (0.74--0.89)**   \<0.001   **0.67 (0.56--0.81)**   \<0.001   **0.81 (0.74--0.88)**   \<0.001
    NO               1987/1892                  0.75 (0.22--2.65)       \<0.001        0.66 (0.23--1.90)       \<0.001    1.08 (0.76--1.55)       0.006     0.72 (0.25--2.09)       \<0.001   0.92 (0.59--1.45)       \<0.001

Abbreviations: HB, hospital-based; PB, population-based; UADT, upper aerodigestive tract.

Values in bold indicate *P*\<0.05.

Regarding the stratified analysis by ethnicity, a decreased cancer risk was also detected amongst Asians under all the genetic models: homozygous model, OR = 0.60, 95% CI = 0.48--0.76; heterozygous model, OR = 0.66, 95% CI = 0.53--0.81; recessive model, OR = 0.82, 95% CI = 0.75--0.91; dominant model, OR = 0.58, 95% CI = 0.47--0.72; and allele comparison, OR = 0.80, 95% CI = 0.72--0.88, and amongst mixed ethnic group: homozygous model, OR = 0.35, 95% CI = 0.13--0.93; heterozygous model, OR = 0.53, 95% CI = 0.37--0.75; recessive model, OR = 0.37, 95% CI = 0.14--0.98; dominant model, OR = 0.46, 95% CI = 0.36--0.60; and allele comparison, OR = 0.50, 95% CI = 0.36--0.68. However, an increased risk of cancer was detected amongst Caucasians under homozygous model (OR = 1.45, 95% CI = 1.05--2.02) and recessive model (OR = 1.45, 95% CI = 1.05--2.00).

Regarding the stratified analysis by cancer type, the *ADH1B* Arg47His polymorphism significantly decreased the risk of esophageal cancer: homozygous model, OR = 0.39, 95% CI = 0.28--0.55; heterozygous model, OR = 0.47, 95% CI = 0.34--0.66; recessive model, OR = 0.72, 95% CI = 0.62--0.83; dominant model, OR = 0.41, 95% CI = 0.31--0.54; and allele comparison, OR = 0.67, 95% CI = 0.57--0.78; upper aerodigestive tract cancer: homozygous model, OR = 0.31, 95% CI = 0.23--0.42; heterozygous model, OR = 0.33, 95% CI = 0.21--0.53; recessive model, OR = 0.70, 95% CI = 0.57--0.86; dominant model, OR = 0.39, 95% CI = 0.26--0.58; and allele comparison, OR = 0.62, 95% CI = 0.54--0.71; and head and neck cancer: homozygous model, OR = 0.55, 95% CI = 0.31--0.97; recessive model, OR = 0.78, 95% CI = 0.66--0.93; dominant model, OR = 0.64, 95% CI = 0.47--0.87; and allele comparison, OR = 0.80, 95% CI = 0.66--0.96.

Regarding the stratified analysis by control source and HWE, a decreased cancer risk was detected in hospital-based studies: homozygous model, OR = 0.53, 95% CI = 0.40--0.71; heterozygous model, OR = 0.64, 95% CI = 0.51--0.81; recessive model, OR = 0.79, 95% CI = 0.69--0.90; dominant model, OR = 0.56, 95% CI = 0.44--0.72; and allele comparison, OR = 0.77, 95% CI = 0.68--0.87; population-based studies: dominant model, OR = 0.68, 95% CI = 0.54--0.85; and allele comparison, OR = 0.87, 95% CI = 0.76--0.99; and also the studies in agreement with HWE: homozygous model, OR = 0.60, 95% CI = 0.48--0.76; heterozygous model, OR = 0.71, 95% CI = 0.60--0.84; recessive model, OR = 0.81, 95% CI = 0.74--0.89; dominant model, OR = 0.67, 95% CI = 0.56--0.81; and allele comparison, OR = 0.81, 95% CI = 0.74--0.88.

Sensitivity analysis and publication bias {#sec3-3}
-----------------------------------------

Substantial heterogeneities were found under all the five genetic models (*P*\<0.001). Therefore, the random-effect model was adopted to assess the ORs and 95% CIs. Furthermore, the leave-one-out sensitivity analyses indicated that no single study could change the pooled ORs. The results of the Begg's funnel plot and Egger's linear regression test showed no evidence of publication bias (homozygous model, *P*=0.227; heterozygous model, *P*=0.697; recessive model, *P*=0.663; dominant model, *P*=0.599; and allele comparison *P*=0.342, see [Figure 3](#F3){ref-type="fig"}).

![Funnel plot analysis to detect publication bias for *ADH1B* Arg47His polymorphism under the allele comparison model](bsr-39-bsr20181915-g3){#F3}

Discussion {#sec4}
==========

Alcohol consumption has been established to be a major factor in the development and progress of cancer \[[@B13]\]. Alcohol is first catalytically oxidized to acetaldehyde, mainly by ADH, and then to harmless acetate by ALDH \[[@B6],[@B7]\]. Acetaldehyde, a Group I human carcinogen classified by the International Agency for Research on Cancer (IARC), may stimulate carcinogenesis by disrupting DNA synthesis and repair \[[@B8],[@B9],[@B84]\]. Therefore, to reduce the risk of cancer, it is important to modulate exposure levels to acetaldehyde in the liver. *ADH1B* gene, also known as *ADH2*, is located on chromosome 4q22 and is the locus responsible for the majority of activities of ADH function \[[@B25]\]. Arg47His (rs1229984 G \> A) in *ADH1B* led to a single amino acid substitution of arginine (Arg) for histidine (His) at codon 47. Compared with the Arg/Arg individuals, the His/His individuals have a 40-fold higher enzyme activity oxidized alcohol to toxic acetaldehyde, thereby inducing tumorigenesis \[[@B25],[@B85]\].

To the best of our knowledge, this is the first meta-analysis investigating the association between *ADH1B* Arg47His polymorphism and the overall cancer risk. A total of 66 studies from 64 articles with 31999 cases and 50964 controls were included, and the large sample size provided adequate power to detect this association. Overall, *ADH1B* Arg47His polymorphism was associated with a decreased risk of overall cancer under all the five genetic models. Stratified analysis by ethnicity revealed that *ADH1B* Arg47His polymorphism reduced cancer risk amongst Asians and mixed ethnicity group but increased risk amongst Caucasians. Stratified analysis by cancer type revealed that *ADH1B* Arg47His polymorphism reduced risk in esophageal cancer, upper aerodigestive tract cancer, and head and neck cancer, while no effect was found on colorectal, hepatocellular, gastric and pancreatic cancer. In stratified analysis by control source and HWE, a decreased cancer risk was detected in hospital-based studies, population-based studies, and also the studies in agreement with HWE.

There were several meta-analyses focussed on *ADH1B* Arg47His polymorphism and only one particular type of cancer risk, such as esophageal, head and neck, gastric and colorectal cancer \[[@B11]\]. For esophageal cancer, Mao et al. \[[@B11]\] found that the 47His allele was significantly associated with the reduced risk of this cancer when compared with the 47Arg allele. And these findings were replicated in our meta-analysis. For head and neck cancer, the 47His allele was also found to be associated with decreased risk of head and neck cancer amongst Asians only under the dominant model \[[@B12]\]. However, similar results were found under the other three models in our analysis, which may be attributed to a larger sample size including eight more studies. Interestingly, Chen et al. \[[@B15]\] found that *ADH1B* Arg47His polymorphism was associated with decreased risk of colorectal cancer supported by four studies. However, this decreased risk was not present in the current one including six more studies. It was noteworthy that we found that *ADH1B* Arg47His polymorphism was associated with decreased cancer risk amongst Asians while increased cancer risk amongst Caucasians. In Caucasian population, the A allele was found to associate with an increased risk of colorectal cancer \[[@B32]\]. The opposite findings may result from the difference of ethnicity with the 47His allele occupied more than 90% amongst Asians but fewer than 20% amongst Caucasians \[[@B7]\]. Furthermore, we re-analyzed the ethnic groups of Asian and Caucasian people. Amongst Asians, a decreased cancer risk was also detected in esophageal cancer and head and neck cancer. While in Caucasians, we did not repeat the results, but an increased cancer risk was detected in colorectal cancer (homozygous model, OR = 1.55, 95% CI = 1.10--2.20 and recessive model, OR = 1.55, 95% CI = 1.11--2.18).

Several limitations in the current meta-analysis should be addressed. First, a number of studies adopted in our meta-analysis had relatively small sample size for each cancer type, like bladder and breast cancer. Second, because of the absence of original data, our analyses were based on unadjusted estimates of ORs without adjustment for other confounding factors. Third, there were substantial heterogeneities in all the five genetic models, hence the random-effect model was adopted and might present unstable results. Overall, due to these limitations, the findings in the current meta-analysis should be interpreted with caution.

In conclusion, our meta-analysis suggested that *ADH1B* Arg47His polymorphism was significantly associated with the decreased overall cancer risk, especially for esophageal cancer and head and neck cancer amongst Asians.
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:   alcohol dehydrogenase

ALDH

:   aldehyde dehydrogenase
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